On Tuesday, the Dow Jones Industrials broke its losing streak, although its gain of just 10 points did little to erase the more than 325 points the Dow had lost on Friday and Monday. Even though ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (LSE:0Q1N) from Buy to Neutral. As of April 2, 2025, the average one-year price target for Pfizer is 31.00 ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (BIT:1PFE) from Buy to Neutral. As of April 4, 2025, the average one-year price target for Pfizer is ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and ...

Pfizer Inc. (NYSE:PFE) is one of the best value stocks in Goldman Sachs’ portfolio. The company appears to have seized an opportunity that may help it strengthen its portfolio with newer therapies in ...

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million in value and announced this year. M&A, however, has not been enough for ...

While Pfizer Inc's (NYSE:PFE) revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs. The Pfizer Analyst: Analyst Asad ...